Garwood Medical Devices

Executive Summary

Garwood Medical Devices is a privately held medical technology company headquartered in Buffalo, New York, dedicated to addressing the challenge of bacterial biofilm infections on medical implants. Its proprietary electrochemical disruption platform uses low-voltage electrical signals to target and eliminate biofilms, enabling implant retention without removal. The lead product candidate, BioPrax™, has received FDA Breakthrough Device designation, which expedites development and regulatory review for serious conditions. Biofilm infections affect millions of patients annually, leading to revision surgeries, increased morbidity, and high healthcare costs. Garwood's technology offers a non-invasive, cost-effective alternative that could shift the standard of care for infected implants. Currently, BioPrax is under investigation for marketing authorization, with ongoing clinical studies supporting its safety and efficacy. The company is poised to submit a premarket approval (PMA) application within the next year, leveraging the Breakthrough Device pathway for faster review. If approved, BioPrax could become the first FDA-cleared biofilm disruption therapy for orthopedic implants, addressing a multi-billion-dollar market. Garwood is also exploring expansions into other implant types, such as cardiovascular and neurological devices. With a strong intellectual property portfolio and strategic partnerships, the company is well-positioned for commercial success following regulatory clearance.

Upcoming Catalysts (preview)

• Q4 2026FDA Marketing Authorization Decision for BioPrax50% success
• Q2 2027Initiation of Pivotal Trial for New Implant Indication70% success
• H1 2027Strategic Partnership or Licensing Deal for Commercialization40% success